Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human EPOR Antibodies:
anti-Mouse (Murine) EPOR Antibodies:
anti-Rat (Rattus) EPOR Antibodies:
Go to our pre-filtered search.
Human Monoclonal EPOR Primary Antibody for cELISA, FACS - ABIN1720915
Winkelmann: The human erythropoietin receptor. in International journal of cell cloning 1993
Show all 5 references for ABIN1720915
Human Polyclonal EPOR Primary Antibody for IF, ELISA - ABIN1531589
Winkelmann, Penny, Deaven, Forget, Jenkins: The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. in Blood 1990
Show all 3 references for ABIN1531589
Human Polyclonal EPOR Primary Antibody for IF, ELISA - ABIN1532606
Jones, DAndrea, Haines, Wong: Human erythropoietin receptor: cloning, expression, and biologic characterization. in Blood 1990
Show all 3 references for ABIN1532606
Human Polyclonal EPOR Primary Antibody for EIA, FACS - ABIN952118
Lim, Ketchem, Borges, Carabeo, Carter, Hoover, Hu, Wittekind, Zhou, Mehlin: A diversity of antibody epitopes can induce signaling through the erythropoietin receptor. in Biochemistry 2010
Dog (Canine) Polyclonal EPOR Primary Antibody for WB - ABIN2781766
Sinclair, Rogers, Busse, Archibeque, Brown, Kassner, Watson, Arnold, Nguyen, Powers, Elliott: Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. in British journal of cancer 2008
These results identify EPOR as the secondbona fidehydroxylation-dependent substrate of VHL (show VHL Antibodies) that potentially influences oxygen homeostasis and contributes to the complex genotype-phenotype correlation in VHL (show VHL Antibodies) disease.
We report for a first time that functional EpoR is expressed in human rhabdomyosarcoma cell lines as well as by primary tumors from RMS patients.
erythrocyte lineage enforces exclusivity through upregulation of EKLF (show KLF1 Antibodies) and its lineage-specific cytokine receptor (show EBI3 Antibodies) (EpoR) while inhibiting both FLI-1 (show FLI1 Antibodies) and the receptor TpoR (show MPL Antibodies) (also known as MPL (show MPL Antibodies)) for the opposing megakaryocyte lineage
A new point mutation in EPOR induces a short deletion in congenital erythrocytosis.
Data show that erythropoietin receptor antagonist EMP9 suppressed hemoglobin synthesis in xenografts of HeLa cells.
Data suggest that erythropoietin receptor (EPOR) could be a target to overcome therapeutic resistance toward ionizing radiation or temozolomide.
basic mechanisms for hypoxia-inducible factor induction of EPO (show EPO Antibodies) expression, and within erythroid progenitors EPOR engagement of canonical Janus kinase 2 (show JAK2 Antibodies)/signal transducer and activator of transcription 5 (show STAT5A Antibodies) (JAK2 (show JAK2 Antibodies)/STAT5 (show STAT5A Antibodies))
transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles
while EPO (show EPO Antibodies) can stimulate NO production, NO in turn can regulate EPOR expression in endothelial cells during hypoxia
The progressive increase of EPO (show EPO Antibodies) and EpoR mRNA can already be observed during the fibrotic-cirrhotic development with a peak of expression rising at tumor formation.
A solution NMR study of the mouse erythropoietin receptor (mEpoR) comprising the transmembrane domain and the juxtamembrane regions reconstituted in dodecylphosphocholine (DPC) micelles.
These data indicate that EpoR signaling is associated with cardiac remodeling following chronic iron deficiency.
We propose that the CID (show CENPA Antibodies)-dependent dimerization system combined with the EpoR intracellular domain and the Gata1 (show GATA1 Antibodies) gene regulatory region generates a novel peroral strategy for the treatment of anemia.
EpoR and its activity are downstream effectors of Klotho (show KL Antibodies) enabling it to function as a cytoprotective protein against oxidative injury.
Expression of EPOR in rod photoreceptors, Muller cells, and amacrine, horizontal, and ganglion cells of the peripheral retina is not required for the maturation, function, and survival of these cells in aging tissue.
Data indicate a Cbl (show CBL Antibodies)/p85 (show ECM1 Antibodies)/epsin-1 (show EPN1 Antibodies) pathway in erythropoietin receptor (EpoR) endocytosis.
Data from knockout mice suggest that adipose tissue-specific disruption of EPO (show EPO Antibodies) receptor does not alter adipose tissue expansion, adipocyte morphology, insulin (show INS Antibodies) resistance, inflammation, or angiogenesis.
the EPO (show EPO Antibodies)-EPOR system may play a role in glucose metabolism within adipocytes.
EPOR regulates transcriptome for primary progenitors, including Tnfr (show TNFRSF1A Antibodies)-sf13c as a novel mediator of EPO (show EPO Antibodies)-dependent erythroblast formation.
This gene encodes the erythropoietin receptor which is a member of the cytokine receptor family. Upon erythropoietin binding, this receptor activates Jak2 tyrosine kinase which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated erythropoietin receptor appears to have a role in erythroid cell survival. Defects in the erythropoietin receptor may produce erythroleukemia and familial erythrocytosis. Dysregulation of this gene may affect the growth of certain tumors. Alternate splicing results in multiple transcript variants.
, Erythropoietin receptor
, type I single-transmembrane cytokine receptor
, erythropoietin receptor-like